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Spinocerebellar ataxia type 5 (SCA5) is an autosomal dominant neurodegenerative disorder caused by
mutations in b-III spectrin. A mouse lacking full-length b-III spectrin has a phenotype closely mirroring symp-
toms of SCA5 patients. Here we report the analysis of heterozygous animals, which show no signs of ataxia
or cerebellar degeneration up to 2 years of age. This argues against haploinsufficiency as a disease mech-
anism and points towards human mutations having a dominant-negative effect on wild-type (WT) b-III spec-
trin function. Cell culture studies using b-III spectrin with a mutation associated with SCA5 (L253P) reveal
that mutant protein, instead of being found at the cell membrane, appears trapped in the cytoplasm associ-
ated with the Golgi apparatus. Furthermore, L253P b-III spectrin prevents correct localization of WT b-III spec-
trin and prevents EAAT4, a protein known to interact with b-III spectrin, from reaching the plasma membrane.
Interaction of b-III spectrin with Arp1, a subunit of the dynactin–dynein complex, is also lost with the L253P
substitution. Despite intracellular accumulation of proteins, this cellular stress does not induce the unfolded
protein response, implying the importance of membrane protein loss in disease pathogenesis. Incubation at
lower temperature (258C) rescues L253P b-III spectrin interaction with Arp1 and normal protein trafficking to
the membrane. These data provide evidence for a dominant-negative effect of an SCA5 mutation and show for
the first time that trafficking of both b-III spectrin and EAAT4 from the Golgi is disrupted through failure of the
L253P mutation to interact with Arp1.
INTRODUCTION
Spinocerebellar ataxia type 5 (SCA5) is an autosomal domi-
nant neurodegenerative disease. It is characterized by gait
and limb ataxia, dysarthria and uncoordinated eye movements,
and arises from dysfunction and degeneration of the cerebel-
lum (1–3). Different mutations in the gene encoding b-III
spectrin (SPTBN2) were identified as the genetic cause of
SCA5 in three independent families (3).
Spectrins are heterotetramers comprising two a- and two
b-subunits. The a- and b-subunits associate laterally,
forming anti-parallel heterodimers which interact
head-to-head to form the functional heterotetramer (4,5).
Short actin filaments then link the spectrin tetramers together
forming a flexible spectrin network attached to the inner leaf
of the membrane bilayer. They were originally discovered in
erythrocytes and shown to be critical for mechanical support
and maintenance of structural membrane integrity, with
defects resulting in hereditary elliptocytosis and spherocytosis
(6–9). Spectrins also play important roles in stabilizing cell–
cell contacts and localizing ion channels and cell adhesion
molecules within specific subdomains of the plasma mem-
brane (10–12).
Vertebrates have two a-subunits (aI/aII), four b-subunits
(bI–bIV) and a b-H subunit creating diversity and specializ-
ation of function (13). The mammalian erythrocyte spectrin
(aI/bI) is found in striated muscle and a subset of neurons,
whereas aII/bII, aII/bIII and aII/bIV are the major forms in
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non-erythroid vertebrate tissues. b-III spectrin is primarily
expressed in the nervous system, with the highest levels of
expression in the cerebellum, where it is found in Purkinje
cell soma and dendrites (14,15). Originally, it was shown to
associate with the Golgi apparatus (16), but this staining is
now thought to have arisen from antibody cross-reactivity
(17). We have previously shown b-III spectrin to stabilize
EAAT4, the glutamate transporter predominantly expressed
in Purkinje cells, at the cell surface (15). Other investigators
have found the N-terminal actin-binding region of b-III spec-
trin interacts with Arp1, a subunit of the dynactin–dynein
complex (18). A role for b-III spectrin in dynein-mediated
vesicular transport is implied by observation of axonal trans-
port defects in Drosophila expressing mutant forms of b spec-
trin, which are exacerbated by the expression of mutant dynein
and dynactin (19).
We recently generated a functional b-III spectrin knockout
mouse (b-III2/2) and found that from a young age it showed
characteristic features of cerebellar ataxia, suggesting a loss
of b-III spectrin function underlies SCA5 pathogenesis
(20). Since the human disease is autosomal dominant, this
finding indicates that either the mutant forms of b-III spec-
trin are simply inactive and the disease arises from haplo-
insufficiency or, in addition to being non-functional, the
mutant subunits also have a dominant-negative effect and
suppress the function of wild-type (WT) spectrin. In order
to investigate these two possibilities, we analysed heterozy-
gous animals for signs of motor deficits and cerebellar
degeneration. We show here that even at 2 years of age, het-
erozygous animals show no signs of ataxia or cerebellar
pathology. Instead, using cell culture studies, we provide evi-
dence that b-III spectrin containing a mutation associated
with SCA5 (L253P) has a dominant-negative effect on WT
protein function and interferes with membrane protein traf-
ficking.
RESULTS
Heterozgous b-III1/2 spectrin mice show no signs of ataxia
or cerebellar degeneration
We previously reported that homozygous b-III spectrin-
deficient mice (b-III2/2) develop characteristics of ataxia
including a wider hind-limb gait, progressive motor incoordina-
tion, cerebellar atrophy and Purkinje cell loss (20). To determine
whether heterozygous (b-III+/2) mice eventually show signs of
ataxia, we carried out behavioural tests and histological analysis
on mice aged 6 months to 2 years of age. Analysis of footprint
patterns showed no significant difference in base width or
stride length between b-III+/2 and WT littermates (Fig. 1A).
There was also no significant difference in motor performance
between the genotypes, heterozygous animals performing as
well as WT controls on a stationary rod (Fig. 1B), an elevated
beam (Fig. 1C) and a rotating rod task (Fig. 1D).
Cerebellar sections stained for Nissl demonstrated that the
size and morphology of the cerebellum appeared normal in
2-year old b-III+/2 mice, apart from slight differences in
folia I and II (Fig. 2A1 and B1). Immunostaining for calbindin
showed no changes to Purkinje cell morphology in b-III+/2
mice (Fig. 2A2 and A3, and B2 and B3), whereas quantifi-
cation of Purkinje cell density and molecular layer thickness
revealed no cell loss or cerebellar atrophy (WT, 39.6+ 3.4;
b-III+/2, 37+ 8.6 cell/mm; P ¼ 0.73 and WT, 181.7+ 7.1;
b-III+/2, 197.7+ 11.4 mm; P ¼ 0.37; n ¼ 3 of each geno-
type). We also saw no significant reduction in glutamate trans-
porter levels in b-III+/2 mice (Fig. 2C), providing additional
evidence that the loss of EAAT4 and GLAST in b-III2/2 mice
(20) may be important aspects of disease pathogenesis. There-
fore, b-III+/2 mice display none of the characteristics of
cerebellar ataxia, arguing against haploinsufficiency as a
disease mechanism in the mouse, and hence arguing for a
Figure 1. Progressive motor deficits not seen in heterozygous b-III+/2 mice. (A) Footprint analysis, base width and stride length of 6-month to 2-year old mice.
(B) Ability to remain on stationary rod. Mice were given four consecutive trials, with maximum time of 60 s. (C) Number of hind-limb slips age-matched WT
and b-III+/2 mice made when crossing narrow, elevated beam. (D) Latency of WT and b-III+/2 animals to fall from rotarod at 3, 5 and 10 rpm. Mice were given
four trials per day and allowed a maximum retention time of 120 s per trial. All data are means+SEM (WT n ¼ 3–7, b-III+/2 n ¼ 7–9).
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dominant-negative effect of mutant b-III spectrin on WT b-III
spectrin function associated with SCA5.
b-III spectrin associates with the Golgi apparatus when
Leu253 is substituted by proline
To investigate potential dominant-negative effects, we trans-
fected Neuro2a and human embryonic kidney (HEK) 293T
cells with constructs encoding either myc-tagged WT b-III
spectrin or b-III spectrin containing a mutation associated
with SCA5. The missense mutation (L253P) found in one
family with SCA5 was introduced by site-directed
mutagenesis into rat b-III spectrin cDNA. The leucine 253
residue and the N-terminus of b-III spectrin are highly con-
served from fly to human (3). Immunostaining with an
anti-c-myc antibody revealed that, unlike WT, L253P b-III
spectrin appears to accumulate in a discrete intracellular
location and is no longer found at the plasma membrane
(Fig. 3A). No difference in the cellular distribution was seen
between the two cell lines examined. We therefore used
Neuro2a cells, unless otherwise stated, for all subsequent
experiments since b-III spectrin is predominantly a neuronal
protein (14–16). To elucidate the intracellular distribution,
we co-expressed b-III spectrin constructs with either a Golgi
or an endoplasmic reticulum (ER) marker. This revealed that
L253P b-III spectrin appears to associate with the Golgi
apparatus (Fig. 3B).
To determine the effect of L253P b-III spectrin on WT
protein, we co-expressed yellow fluorescent protein (YFP)-
tagged WT b-III spectrin with myc-tagged L253P b-III spec-
trin. We found that the presence of L253P b-III spectrin
resulted in WT b-III spectrin–YFP being trapped in the
same intracellular location as L253P (Fig. 3C). In contrast,
WT b-III spectrin–YFP was found at the plasma membrane
when myc-tagged WT b-III spectrin was co-expressed. This
finding suggests that the presence of the L253P missense
mutation confers a dominant-negative effect on WT b-III
spectrin protein.
L253P b-III spectrin interferes with protein trafficking
and fails to interact with Arp1
EAAT4 is known to interact directly with and be stabilized at
the cell membrane by b-III spectrin (15). Moreover, a decrease
in EAAT4 protein is seen in young b-III2/2 mice (20) and
dramatic changes in EAAT4 distribution are seen in SCA5
autopsy tissue (3). Taken together, these findings suggest
that EAAT4 may play an important role in disease patho-
genesis. We therefore examined what effect the expression
of L253P b-III spectrin had on EAAT4 cellular distribution.
Immunofluorescence microscopy revealed accumulation of
EAAT4 at the Golgi apparatus when L253P was co-expressed
compared with WT b-III spectrin, suggesting a disruption to
protein trafficking (Fig. 4A). To test whether a lower tempera-
ture could rescue the defect, we incubated transfected cells at
258C for an additional 12 h before immunostaining. We found
that the permissive temperature resulted in L253P b-III spec-
trin reaching the plasma membrane (Fig. 4B). Western blot
analysis confirmed protein levels were not altered by the temp-
erature shift but did show that the expression of L253P b-III
spectrin was less than WT protein (Fig. 4B). In addition
EAAT4 was no longer trapped intra-cellularly in cells expres-
sing L253P b-III spectrin when incubated at the lower temp-
erature (Fig. 4C).
A role for b-III spectrin in vesicular trafficking has been
proposed given its ability to interact with Arp1 and copurify
with dynein and dynactin on intracellular vesicles from rat
brain (18). We used a biomolecular fluorescence comple-
mentation (BiFC) assay to investigate whether the L253P
mutation interfered with the ability of the N-terminus of
b-III spectrin to interact with Arp1. The BiFC technique
is based on the generation of a fluorescent signal when
Figure 2. No cerebellar pathology in b-III+/2 mice. Histological analysis of
cerebellum from 2-year old WT (A) and b-III+/2 (B) mice. (A1, B1)
Cresyl violet stain shows whole cerebellar morphology. (A2–B3) Calbindin
immunostaining reveals Purkinje cell morphology (ML, molecular layer;
PCL, Purkinje cell layer; scale bars: A1 and B1, 500 mm; A2 and B2,
50 mm; A3 and B3, 20 mm). (C) Representative western blot and densitometry
data quantifying levels of plasma membrane glutamate transporters in
2-year-old b-III+/2 and WT animals. EAAT4 levels normalized with calbin-
din, a Purkinje cell specific marker. GLAST and GLT1 normalized with actin.
All data are means+SEM (n ¼ 3 of each genotype).
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the two halves of enhanced YFP are brought together,
mediated by the association of two interacting partners
fused to the YFP fragments (21,22). We cloned full-length
Arp1 and the N-terminus of b-III spectrin (amino acids
1–294) downstream of the N-terminal (YN) and C-terminal
fragments (YC) of YFP, respectively, and transfected HEK
293T cells with the expression vectors. Co-expression of
YN–Arp1 and WT YC–b-III spectrin yielded fluorescence,
but no fluorescence was observed when L253P YC–b-III
spectrin was co-expressed with YN-Arp1 (Fig. 4D), indicat-
ing that the mutation does indeed eliminate the interaction
between b-III spectrin and Arp1. However, incubation at
258C for an additional 12 h produced a fluorescence
signal (Fig. 4D), suggesting that a conformational change
underlies the observed lack of interaction at 378C.
Western blot analysis confirmed that all proteins were
expressed at 378C.
Unfolded protein response not induced by L253P
expression
A number of neurodegenerative diseases have been shown to
be associated with the accumulation of abnormal protein,
impaired ER homeostasis and activation of the unfolded
protein/endoplasmic stress response (UPR) (23–26). The
UPR can be triggered by a block in trafficking at the ER
and Golgi, as well as the accumulation of unfolded or mis-
folded proteins in the ER. Therefore, since L253P appears to
accumulate intra-cellularly and disrupt the trafficking of
proteins through the Golgi, we investigated whether the
UPR was induced by the expression of L253P.
We looked at increased expression levels and nuclear trans-
location of the transcription factor growth arrest and DNA
damage/C/EBP-homologous protein (GADD153/CHOP), a
commonly used indicator of ER stress and thought to be a
downstream effector of all three UPR pathways (27,28).
Western blot analysis revealed no difference in the level of
CHOP protein when L253P b-III spectrin was expressed com-
pared with WT b-III spectrin (Fig. 5A and B). CHOP levels
were normalized to those obtained when GFP was overex-
pressed, and the pharmacological induction of ER stress
using tunicamycin, a blocker of N-linked glycosylation, con-
firmed the ability to induce CHOP expression in the cell
culture system. Immunofluorescence microscopy confirmed
the absence of CHOP activation in cells transfected with
L253P as no nuclear staining was observed, in comparison
with high levels observed in tunicamycin-treated cells
(Fig. 5C). Finally, we only saw a small increase in the
expression of CHOP in symptomatic b-III2/2 mice compared
with litter mate controls (116+ 7.8% of WT; n ¼ 4 of each
genotype; P ¼ 0.11). These data suggest that UPR is not a
major consequence of b-III spectrin loss and is unlikely to
underlie the Purkinje cell degeneration observed in the
b-III2/2 mouse model of ataxia. Furthermore, UPR appears
not to be a downstream effect of a b-III spectrin mutation
associated with SCA5.
Figure 3. Cellular localization of full-length L253P b-III spectrin overlaps with Golgi marker. (A) Neuro2a and HEK293 cells transfected with either myc-
tagged WT or L253P b-III spectrin, fixed and stained using anti-c-myc antibody. Nucleus stained with DAPI (blue). (B) Neuro2a cells cotransfected with
either a Golgi (green) or ER (green) marker and myc-tagged WT or L253P b-III spectrin (red). Nucleus stained with DAPI (blue). (C) Neuro2a cells cotrans-
fected with YFP-tagged WT b-III spectrin and either myc-tagged WT or L253P b-III spectrin. Cells immunostained using anti-c-myc antibody (red) and
anti-GFP antibody (green). All images are representative of three independent experiments (scale bar, 10 mm).
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DISCUSSION
A number of dominantly inherited human diseases have
recently been shown to arise from haploinsufficiency (29–
31). Often in these cases, the genes involved encode proteins
where a correct stoichiometry is vital for function and a
single WT gene copy is insufficient. Examples are transcrip-
tion factors or proteins that form macromolecular complexes.
Since spectrin functions as a heterotetramer and assembly
appears to be rate limited by the b subunit (32), one possibility
is that SCA5 arises from b-III spectrin haploinsufficiency due
to the mutant b polypeptides failing to associate with other
subunits. Here we provide strong evidence that haploinsuffi-
ciency is unlikely to be the disease mechanism, as we see
no signs of motor deficits or cerebellar degeneration in hetero-
zygous b-III+/2 mice even at 2 years of age. This indicates
that the loss of b-III spectrin function, thought to be important
in disease pathogenesis (20), must arise from mutations associ-
ated with SCA5 having a dominant-negative effect on WT
b-III spectrin function. It is possible that the heterozygous
animals do not live long enough for a phenotype to be detected
or the motor tasks used are not sensitive enough to detect
minor motor deficits. However, our cell culture studies do
indicate that the proline substitution found in one SCA5
family (L253P) appears to have a dominant-negative effect
on WT b-III spectrin, preventing protein trafficking from the
Golgi apparatus.
Previously, b-III spectrin was shown to stabilize EAAT4 at
the plasma membrane (15) and, using total internal reflection
fluorescence microscopy, Ranum and co-authors (3) revealed
that the in-frame deletion found in the Lincoln SCA5 pedigree
fails to stabilize EAAT4 at the cell surface to the same extent
as WT b-III spectrin. Here we now show that b-III spectrin
also has a role in the vesicular trafficking of EAAT4 from
the Golgi to the plasma membrane and the L253P mutation
disrupts this process. The observation that a large number of
vesicles are found surrounding Golgi cisternae in b-III2/2
mice (20) supports this cellular function. Further we have
shown that the L253P substitution prevents the normal inter-
action between Arp1 and the N-terminus of b-III spectrin.
Based on their work in Drosophila, a link between defects
in the dynein–dynactin complex and SCA5 pathogenesis is
suggested by Lorenzo et al. (19). When flies overexpressing
mutant human b-III spectrin (the Lincoln mutation) were
crossed with either a hypomorphic dynein heavy chain allele
or a dominant mutation in the p150Glued subunit of dynactin,
the larvae displayed exacerbated posterior paralysis and
slowing of vesicle transport, inferring a synergistic effect
between spectrin and dynein–dynactin. Similarly, the rough
eye phenotype in flies overexpressing either the Lincoln or
the L253P mutation was enhanced by the dynein–dynactin
mutants. Here we provide the first direct evidence that a
SCA5 mutation interferes with the ability of spectrin to inter-
act with a component of the dynactin complex, highlighting
Figure 4. L253P b-III spectrin does not interact with Arp1 and interferes with protein trafficking. (A) Neuro2a cells cotransfected with EAAT4 and either myc-
tagged WT or L253P b-III spectrin. Cells immunostained using anti-c-myc antibody (red), anti-EAAT4 antibody (green) and nucleus stained with DAPI (blue).
(B) Cells transfected with either myc-tagged WT or L253P b-III spectrin and 24 h after transfection incubated at 37 or 258C for a further 12 h. Cells immuno-
stained using anti-c-myc antibody (red). Western blot analysis of cell homogenates probed with anti-c-myc antibody. (C) Cells expressing myc-tagged L253P
b-III spectrin and EAAT4 incubated at 258C for a further 12 h. Cells immunostained using anti-c-myc antibody (red) and anti-EAAT4 antibody (green). (D)
BiFC assay using cells transfected with Arp1 fused to the N-terminal half of YFP (YN-Arp1) and the actin-binding region of b-III spectrin, with or without
the L253P substitution, fused to the C-terminal half of YFP (YC-b-III). Twenty-four hours after transfection cells were incubated at 37 or 258C for a further
12 h. Western blot analysis of cell homogenates probed with anti-GFP antibody. All images are representative of three independent experiments (scale bar,
10 mm).
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how normal trafficking can be disrupted in SCA5. The fact
both the interaction with Arp1 and protein trafficking defects
were rescued by incubating at a lower temperature suggests
that the L253P substitution results in a protein conformation
defect. Ongoing work by Ranum and colleagues supports
temperature sensitivity of conformation of the mutant human
protein (K.A. Dick Krueger and L.P.W. Ranum personal com-
munication). Importantly, a direct role for dynein in the trans-
port of proteins into dendrites has recently been shown (33),
supporting the possibility that interfering with Arp1 binding
will result in defects to protein trafficking within the Purkinje
cell dendritic tree of SCA5 patients.
Irrespective of the mechanism, the intracellular accumu-
lation of proteins can lead to ER stress, the induction of
UPR, and apoptotic cell death. However, we see no major
induction of GADD153/CHOP, a downstream effector of
UPR in transfected cells or in symptomatic b-III2/2 mice.
Taken together, these results suggest that unlike other neuro-
degenerative disorders, the disease mechanism in SCA5 does
not involve the induction of UPR. Instead, the actual loss of
membrane proteins and their cellular functions appears to be
more critical for disease pathogenesis. The expression of
mutant forms of b-III spectrin in Purkinje cells and identifi-
cation of other membrane proteins that are altered will be fun-
damental to fully understanding the mechanisms of Purkinje
cell dysfunction and degeneration. The N-terminus of b spec-
trin is known to bind actin and 4.1, forming a spectrin/4.1/
actin junction. Protein 4.1 has been shown to bind several
membrane proteins and be required for their stable cell-surface
expression (34–36). Incorporation of a mutant b subunit could
alter the conformation of the whole tetramer preventing
normal function and interaction with proteins including
protein 4.1. Future research should investigate whether differ-
ent mutations associated with SCA5 alter the ability of b-III
spectrin to interact with components of the dynein–dynactin
complex or with protein 4.1.
In summary, the present work has shown that mutant b-III
spectrin disrupts protein trafficking from the Golgi apparatus
through elimination of normal interaction between b-III
spectrin and the dynactin component Arp1. This helps
explain the mislocalization of membrane proteins seen in
SCA5. Furthermore, haploinsufficiency is not supported as a
disease mechanism as indicated by a lack of disease phenotype
in mice heterozygous for loss of b-III spectrin.
MATERIALS AND METHODS
Analysis of b-III1/2 mice
All genotyping, motor tasks, histology and western blotting
analysis were carried out as previously described (20).
Seven days prior to the behavioural tests, old mice were habi-
tuated to the test environment by handling (10 min each day).
Antibodies
Sagittal cerebellar sections were immunostained using mouse
anti-calbindin D (1:50) and cyanine 3 (Cy3)-conjugated goat
anti-mouse IgG (Jackson Laboratories). Mouse anti-c-myc
(Ab-1, Calbiochem) and either Cy3- or Cy2-conjugated goat
anti-mouse IgG (Jackson Laboratories) were used to detect
pRK5-myc-tagged constructs. YFP-tagged b-III spectrin was
detected with rabbit anti-GFP (Molecular Probes, Invitrogen)
and fluorescein isothiocyanate-conjugated goat anti-rabbit
IgG (Cappel). Polyclonal antibodies against EAAT4,
GLAST and GLT1 were a kind gift of Jeffrey Rothstein, and
mouse anti-actin, -calbindin and rabbit anti-GADD153
obtained from Sigma and Santa Cruz, respectively.
Figure 5. No induction of unfolded protein response by L253P b-III spectrin compared with WT b-III spectrin. (A) Total cellular homogenates of Neuro2a cells
transfected with constructs encoding GFP, WT b-III spectrin, L253P b-III spectrin or untransfected cells treated with tunicamycin for 12 h resolved by SDS–
PAGE, and immunoblotted using anti-GADD153 antibody. (B) Data quantified by densitometry (means+SEM). (C) Representative confocal images of cells
immunostained for CHOP (green) and nucleus stained with DAPI (blue). Scale bar, 10 mm. (D) Total cerebellar homogenates of symptomatic b-III2/2 and
age-matched WT mice resolved by SDS–PAGE, immunoblotted using anti-GADD153 antibody.
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Plasmids
The missense mutation L253P was introduced using the
QuickChange site-directed mutagenesis kit (Stratagene) accord-
ing to the manufacturer’s instructions using pRK5-myc-tagged
b-III spectrin as template and 5′-GGCCTGACGAAGC
CCCTGGATCCTGAAG-3′ and 5′- CTTCAGGATCCAGG
GGCTTCGTCAGGCC-3′ as primers. Full-length WT b-III
spectrin and the first 294 amino acids of WT and L253P b-III
spectrin were amplified by PCR using primers that introduced
either NotI and ClaI (5′-ATTTGCGGCCGCATGAGCA
GCACCCTGTCACCCA-3′ and 5′-CCATCGATTTTGTTCTT
CTTAAAGAAGCTGAAT-3′) or BspEI and XbaI (5′-CCTC
CGGAATGAGCAGCACCCTGTCACCCA-3′ and 5′-GCTC
TAGACTAGCCAATTCTTTTGCCTTCCAC-3′) restric-
tion sites, respectively, and the products cloned into
pcDNA3.1(zeo)-YC vector (kind gift of Stephen Michnick).
Full-length Arp 1 was amplified using Quickclone cDNA (Clon-
tech) as template and cloned into the BspEI and XbaI sites of
pcDNA3.1(zeo)-YN. Other plasmids were pCDNA3.1 rat
EAAT4 (15) and Golgi (pECFP-golgi) and ER (pDsRed2-ER)
markers from Clontech.
Cell culture and transfections
HEK 293T cells were grown in minimum essential medium
(MEM, Sigma) containing 10% fetal bovine serum, 10 mM
glutamine, 1× non-essential amino acids and antibiotics
(penicillin and streptomycin). Mouse neuronal 2a (N2a) cells
were grown in Dulbecco’s modified Eagle’s medium
(DMEM, Gibco) containing the aforementioned components
and supplemented with 4.5 g/l glucose and 0.11 g/l sodium
pyruvate (Gibco). For cell homogenates, cells were plated
onto 35 mm dishes and for microscopic observation cells
were plated onto poly-L-lysine-coated coverslips in 35 mm
dishes. A total of 2 mg of DNA was used to transfect cells
with Fugene HD at a ratio of 3:2 according to the manufac-
turer’s instructions (Roche). Twenty-four hours post-
transfection cells were either harvested for western blot
analysis, fixed with 4% paraformaldehyde for immunostain-
ing, maintained at 37 or 258C for an additional 12 h (to test
for temperature sensitivity shown by K.A. Dick Krueger et
al., manuscript submitted) or treated with 2 mg/ml tunicamy-
cin (Calbiochem) for 12 h. All coverslips were mounted
using hard set vectashield containing DAPI unless
Cy2-conjugated goat anti-mouse IgG was used. In this
instance, vectashield was used as mounting agent (Vector Lab-
oratories, Burlingame, CA, USA).
Microscopy
Images were captured with an Olympus BX51 microscope or
using a Zeiss Axiovert confocal laser scanning microscope.
All acquisition settings were kept constant between samples,
and colours were applied using Image J.
Statistics
Statistical analysis was performed using Student’s t-test, two
sample assuming unequal variance, apart from densitometry
analysis of western blots where one sample t-test was used
with a predicted value of 100% for the WT.
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